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Abstract
Objectives. Innovative post-remission therapies are needed to
eliminate residual AML cells. DC vaccination is a promising
strategy to induce anti-leukaemic immune responses. Methods.
We conducted a first-in-human phase I study using TLR7/8-
matured DCs transfected with RNA encoding the two AML-
associated antigens WT1 and PRAME as well as CMVpp65. AML
patients in CR at high risk of relapse were vaccinated 109 over
26 weeks. Results. Despite heavy pretreatment, DCs of sufficient
number and quality were generated from a single leukapheresis in
11/12 cases, and 10 patients were vaccinated. Administration was
safe and resulted in local inflammatory responses with dense T-cell
infiltration. In peripheral blood, increased antigen-specific CD8+ T
cells were seen for WT1 (2/10), PRAME (4/10) and CMVpp65 (9/10).
For CMVpp65, increased CD4+ T cells were detected in 4/7 patients,
and an antibody response was induced in 3/7 initially seronegative
patients. Median OS was not reached after 1057 days; median RFS
was 1084 days. A positive correlation was observed between
clinical benefit and younger age as well as mounting of antigen-
specific immune responses. Conclusions. Administration of TLR7/8-
matured DCs to AML patients in CR at high risk of relapse was
feasible and safe and resulted in induction of antigen-specific
immune responses. Clinical benefit appeared to occur more likely
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Australian and New Zealand Society for Immunology Inc.
2020 | Vol. 9 | e1117
Page 1
Clinical & Translational Immunology 2020; e1117. doi: 10.1002/cti2.1117
www.wileyonlinelibrary.com/journal/cti
in patients <65 and in patients mounting an immune response.
Our observations need to be validated in a larger patient cohort.
We hypothesise that TLR7/8 DC vaccination strategies should be
combined with hypomethylating agents or checkpoint inhibition
to augment immune responses. Trial registration. The study was
registered at https://clinicaltrials.gov on 17 October 2012
(NCT01734304) and at https://www.clinicaltrialsregister.eu
(EudraCT-Number 2010-022446-24) on 10 October 2013.
Keywords: acute myeloid leukaemia, cancer vaccines, clinical trials,
dendritic cell vaccination, immunotherapy
INTRODUCTION
Despite improvements in outcome over the past
decades, with 5-year survival rates climbing from
6.2% in 1975–1977 to 28.1% in 2008–20141 acute
myeloid leukaemia (AML) still has a dismal
prognosis.2 The major reason for the poor survival
rate is the high risk of relapse after intensive
induction therapy. The most successful strategy to
reduce the relapse rate is allogeneic
haematopoietic stem cell transplantation (allo-
HSCT).3 This potentially curative cellular
immunotherapy is based on the graft-versus-
leukaemia effect of allogeneic T cells. However,
because of high morbidity and mortality of this
therapy, there is a large group of AML patients
without this therapeutic option. Alternative
strategies for the activation of the immune system
aiming at eradication of chemorefractory residual
disease are therefore urgently sought after.
Vaccines induce and enhance autologous T cells
targeting intracellular leukaemia-associated
antigens (LAAs) and represent a promising
strategy. Immunisation with LAA peptides has
been studied in several clinical trials with
moderate clinical success so far.4,5 Optimisation of
vaccination might be achieved by the use of DCs.
As professional antigen-presenting cells, they
represent physiological candidates to induce
strong and durable immune responses.6,7 Several
strategies have been applied including
hybridomas of autologous DCs fused with
leukaemic blasts from primary diagnosis as a
vaccine in 17 AML patients in CR. Immunological
responses were observed, and 71% of the patients
were still in CR at a median follow-up of almost
5 years.8 Results of two major studies using
monocyte-derived DCs loaded with LAAs for post-
remission treatment of AML patients have been
reported: vaccination with DCs electroporated
with mRNA encoding hTERT resulted in antigen-
specific T-cell responses in 11/19 patients; RFS
after a median observation time of 52 months
was 58%.9 Within a phase II trial, an anti-
leukaemic response was detected in 13/30 patients
vaccinated with DCs loaded with wilms tumor 1
(WT1) mRNA. A molecular remission defined by
WT1 qPCR in the peripheral blood was achieved
in 9/30 patients, and RFS and OS at 5 years were
30.8% and 50.0%, respectively.10 In both
publications, DC maturation was achieved by a
combination of pro-inflammatory cytokines and
prostaglandins.11 While this protocol was
designed to promote migratory and
immunostimulatory properties of DCs, no IL-12p70
production was induced. However, IL-12 is a
crucial cytokine for both Th1 polarisation and NK
cell activation. In preclinical work comparing DCs
generated from peripheral blood mononuclear
cells (PBMCs) of healthy controls using different
maturation cocktails, we could show that the
addition of a toll-like receptor (TLR) 7/8 ligand to
the DC maturation cocktail results in enhanced T-
cell stimulation. In direct comparison to DCs
matured without a TLR agonist, the resulting DCs
are characterised by a higher expression of the
costimulatory molecules CD80 and CD86 and very
high production of bioactive IL-12p70. Both
in vitro and in vivo, we could show that these DCs
stimulate strong immune responses including
polarisation of CD4+ T cells to Th1, induction of
antigen-specific CD8+ T cells and activation of NK
cells.12,13 This approach can be translated to
monocytes derived from AML patients in CR, also
resulting in IL12p70-producing DCs with very
similar functional characteristics.14
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Hence, we have developed a good
manufacturing practice (GMP)-compliant protocol
for the generation of next-generation DCs,
combining a short, only 3-day differentiation
period with a novel maturation cocktail that
includes the TLR 7/8 agonist R848.15 As accounted
for in detail previously16 mRNAs encoding the
LAAs WT1 and preferentially expressed antigen in
melanoma (PRAME) as well as the viral control
antigen cytomegalovirus (CMV)pp65 were chosen
for antigen loading of three separate batches of
DCs by electroporation. Here, we describe the
results of a phase I first-in-human proof-of-
concept trial using next-generation DCs for post-
remission therapy of 10 AML patients in first CR
with a high risk of relapse (non-favorable risk
group or MRD positivity).
RESULTS
Patient characteristics
The characteristics of the 13 patients who were
enrolled into the study are shown in Table 1.
Twelve patients were positive for WT1 by qPCR at
primary diagnosis, four were positive for PRAME
by qPCR, and CMV serostatus was positive in four
patients before vaccination. Eastern Cooperative
Oncology Group (ECOG) performance status was 0
in two patients, 1 in 10 patients and 2 in one
patient.
Feasibility of vaccine generation and
administration
Twelve patients underwent leukapheresis for
production of the DC vaccine; patient #5
developed a leukaemia relapse in the short time
span between screening and planned
leukapheresis and was excluded from the study
before leukapheresis. Key figures of the
leukapheresis product are presented in
Supplementary table 1. A median of 1.25 9 1010
(range 0.6–2.8 9 1010) viable white blood cells
was collected per patient. Median monocyte yield
was 3.6 9 109 (range 1.0–7.5 9 109). Median DC
yield after electroporation was 3.65 9 108 (range
1.27–5.68 9 108). After quality control and
removal of retain samples, sufficient DCs for the
full schedule of 10 vaccinations (1.5 9 108 DCs)
were produced for 11 of 12 patients. For patient
#2, only six vaccinations were available as the
monocyte yield was low because of an
unexpected decrease in leucocyte count between
screening and leukapheresis (from 5.9 to
3.0 G L1), and as DC recovery after
electroporation was suboptimal. Two patients
completed leukapheresis but were not vaccinated
because of early relapse during vaccine
production (#3) and because of characteristics of
the vaccine (#8, see below). Of the 10 patients
who actually initiated vaccination, seven
underwent the complete regular schedule of 10
vaccinations. Patient #2 received all six
vaccinations that were available, which was the
minimum required by the study protocol; patient
#4 developed a relapse after seven vaccinations
and received two further vaccinations in
combination with one cycle of 5-azacytidine; and
patient #7 also developed a relapse after seven
vaccinations and received three further
vaccinations in combination with two cycles of 5-
azacytidine. Two patients received further DC
vaccinations after the end of the study in
combination with 5-azacytidine in view of an
impending or established relapse: eight
vaccinations with five cycles of 5-azacytidine in
patient #1 and two vaccinations with one cycle of
5-azacytidine in patient #11. Median time from
CR/CRi to first vaccination was 110 days (range 34–
205 days), mainly because of further cycles of
consolidation therapy; median time from
leukapheresis to first vaccination was 25 days
(range 18–38 days).
Vaccine characterisation
All 12 generated DC preparations were tested for
their phenotype, migration capacity, cytokine
secretion, and processing and presentation of the
three selected antigens after RNA electroporation
(Figure 1 and Supplementary figure 1). For all
patients, the cells showed a typical DC phenotype
(CD14low and CD83+; Figure 1a). Expression of
various costimulatory or chemokine receptor
molecules was measured, and the specific
fluorescence intensity (SFI) was calculated
(Figure 1b). Median SFI was 124.6 for HLA-DR, 4.1
for CCR7, 35.6 for CD40, 31.6 for CD80, 35.4 for
CD86, and 21.5 for PD-L1. The ratio of CD86 to
PD-L1 expression as a potential measure of
positive costimulation was 1.25 in median. A
median of 74.5% (range 38.3–98.4%) of DCs
showed migration towards a CCL19 gradient
(Figure 1c). Ten of 12 DC preparations secreted
relatively high amounts of IL-12p70 (median of
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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1845 pg/5 9 106 DC/24 h; range 470–4525 pg/
5 9 106 DC/24 h) and low amounts of IL-10
(median of 17.3 pg/5 9 106 DC/24 h; range 0–
241 pg/5 9 106 DC/24 h), as expected from our
previous experiments.12 DCs of patient #7 showed
very low IL-12p70 production (81.5 pg/5 9 106
DC/24 h) and no IL-10 production. DCs of patient
#8 showed high IL-12p70 production (1969 pg/
5 9 106 DC/24 h), but even higher IL-10
production (3031 pg/5 9 106 DC/24 h; Figure 1d).
Because of the unknown effects of vaccinations
with IL-10-producing DCs in the AML setting, this
patient was excluded from the study and not
vaccinated, although all release criteria for the
vaccine were fulfilled. Successful translation of
the electroporated RNA was proven by
intracellular staining of the DCs for the resulting
proteins (median SFI 2.36 for WT1, 1.44 for
PRAME, 1.53 for CMVpp65); DCs electroporated
with one of the other two RNA molecules served
as control (Figure 1e and Supplementary figure
2). Presentation of the antigens in the context of
HLA molecules was functionally proven by IFN-c
secretion of specific T-cell clones after coculture
with the different DC batches. Each T-cell clone
was preferentially stimulated by the respective
DC batch (Figure 1f).
Vaccine-induced immune responses
For all 10 vaccinated patients, local immune
response was measured 48 h after the fifth
vaccination by size of local erythema and
induration (Figure 2a). Vaccine site reaction was
detectable for all patients and all antigens.
Variability between patients was high, but no
significant differences were found between the
three antigens (WT1: median of 1.43 cm2, range
0.38–4.15 cm2; PRAME: median of 1.04 cm2,
range 0.28–3.46 cm2; CMV: median of 1.24 cm2,
range 0.38–3.14 cm2; Figure 2b). Skin biopsies
were taken from nine patients. Dense CD4+ and
CD8+ T-cell infiltration was seen by
immunohistochemistry (Figure 2c).
Immunomonitoring was performed on PBMCs
and plasma samples obtained before vaccination,
after five vaccinations and at the end of the
study. We found no major changes in the course
of the therapy with respect to absolute and
relative numbers of leucocytes, granulocytes,
monocytes, lymphocytes, CD3+ T cells, CD4+ T
cells, CD8+ T cells, CD19+ B cells or CD3-/CD16_56+
NK cells (data not shown). Antigen-specific T-cellTa
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Figure 1. Characterisation of DC phenotype, migration capacity, cytokine secretion and antigen processing and presentation. For all 12
generated DC preparations, surface expression of (a) the DC markers CD14 and CD83 and (b) various costimulatory or chemokine receptor
molecules was determined by flow cytometry. (c) Migration towards a CCL19 gradient was measured in a trans-well assay (2 technical replicates
per sample). (d) Secretion of IL-10 and IL-12p70 after CD40 ligation was analysed. To prove successful antigen translation and presentation after
RNA electroporation, DCs were (e) intracellularly stained for the resulting proteins and (f) used for stimulation of specific T-cell clones as
measured by IFN-c secretion (n = 3–7). For a, b and e, results are presented in box-and-whisker plots, with boxes representing the lower quartile,
the median and the upper quartile, while the whiskers show the minimal and the maximal values. For all other graphs, data shown reflect mean
and standard deviation.
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responses were measured by ELISpot and by
multimer staining, as shown for representative
patients in Figure 3 (complete immunomonitoring
data of these patients is presented in
Supplementary figure 3). An increased ELISpot
response after vaccination as defined by a ≥ 1.5-
fold increase of antigen-specific spot count was
detected in 2/10 patients for WT1 (Figure 3a), in 4/
10 patients for PRAME (Figure 3b), and in 9/10
patients for CMV (Figure 3c and d; Table 2). These
results were largely reflected by multimer staining:
an increased response as defined by a ≥ 2-fold
increase of multimer-positive CD8+ T cells was
detected in 1/6 patients for WT1, in 0/3 patients
for PRAME, and in 6/8 patients for CMV, with
limitations because of the availability of multimers
for the various HLA types (Table 2 and
Supplementary figure 4). CMV responses were
generally very high, with up to 15.9% of all CD8+
T cells stained with a single CMV multimer after
vaccination in a primarily seropositive patient (#6;
Figure 3g), and up to 9.6% of all CD8+ T cells
stained with a single CMV multimer after
vaccination in a primarily seronegative patient
(#10). Of note, also decreased frequencies after
vaccination were observed (Supplementary figure
3). Post-vaccination LAA-specific T-cell responses
were significantly lower, but still clearly detectable
in some patients (Figure 3e and f). In 4/7 patients
where a CMV-specific multimer for HLA type II was
available, an increase in antigen-specific CD4+ T
cells could be detected as well (Figure 3i; Table 2).
Vaccine-induced B-cell responses were measured
by detection of CMV antibodies. Of seven patients
who were CMV seronegative before vaccination,
antibodies against CMV were detected in three
patients after vaccination (#7, #10, #13), and one
patient had a borderline reaction after
vaccination (#2), while no antibodies against CMV
were detectable in three patients (#4, #9, #11).
Seroconversion as a result of primary CMV
infection was excluded by the methodology.
Clinical responses to vaccination
The vaccination protocol was generally very well
tolerated. All patients observed transient vaccine
site reactions (erythema, induration, pruritus) of
grade 1 intensity. Other frequent adverse events
were musculoskeletal pain (6/10), skin reactions
outside of vaccine sites (5/10), diarrhoea (4/10)
and fatigue (4/10). All potentially treatment-
Figure 2. Vaccine site reaction. (a) For all 10 vaccinated patients and all antigens, erythema and induration of the vaccine sites were observed.
(b) There was high variability between patients, but no significant difference between the three antigens in size of local reaction. (c)
Immunohistochemical analysis of skin biopsies at the vaccine sites revealed dense CD4+ and CD8+ T-cell infiltration (one representative example
shown).
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related adverse events reported by ≥ 2/10 patients
are listed in Supplementary table 2. All adverse
events were transient, and except for one grade 3
pyrexia, all adverse events were graded 1–2.
Because of limited patient numbers in the
phase I setting, clinical efficacy analysis was
purely exploratory. Vaccinated patients have
been observed for a median of 1057 (range
424–1449) days since primary diagnosis and a
median of 811.5 (range 293–1267) days since
first vaccination, with the cut-off on 31 March
2018. A swimmer plot of all 10 vaccinated
patients is depicted in Figure 4. Three patients
(#4, #7 and #11) relapsed already in the course
of the scheduled vaccinations, and two patients
(#1 and #2) relapsed after the end of the trial.
Of these five patients, only one (#4) is still alive
after several salvage therapies. The other five
vaccinated patients are still alive and in ongoing
CR. Aggregated survival data are shown in
Figure 5. Median OS has not yet been reached
(Figure 5a), and median RFS was 1084 days
(Figure 5b), with 50% of patients still relapse-
free at the end of observation. In a hypothesis-
generating analysis, these survival data compare
favorably to a closely matched patient cohort
from the AML-Cooperative Group (AML-CG)
registry (see Supplementary table 3 for patient
characteristics), where median OS was also not
yet reached at the end of observation (P-
value = 0.53; Figure 5a) and median RFS was
only 396 days, closely missing out on statistical
significance in spite of the small trial group (P-
value = 0.09; Figure 5b). Exploratory subgroup
analysis within the study cohort showed that
patients ≤ 65 years had significantly better OS
Figure 3. Representative examples of vaccine-induced immune responses. (a–d) PBMCs isolated before and after vaccination were tested for
antigen-specific T cells by ELISpot. Increased immune responses were detected for the LAAs WT1 (a) and PRAME (b) as well as for CMVpp65
(c, d). Both expansion of pre-existing immune responses (c) and induction of novel immune responses (d) were observed. (e–h) PBMCs isolated
before and after vaccination were tested for antigen-specific CD8+ T cells by multimer staining. Increased immune responses were detected for
the LAAs WT1 (e) and PRAME (f) as well as for CMVpp65 (g, h). Both expansion of pre-existing immune responses (g) and induction of novel
immune responses (h) were observed. (i) For CMVpp65, induction of antigen-specific CD4+ cells was also detected.
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(median not yet reached vs. 628 days; P-value =
0.0008; Figure 5c) and RFS (median not yet
reached vs. 294 days; P-value = 0.0122; Figure
5d) than patients > 65 years. Immune responders
as defined by expansion of antigen-specific T
cells against WT1 or PRAME showed a trend
towards better OS (median not yet reached vs.
976 days; Figure 5e) and RFS (median not yet
reached vs. 509 days; Figure 5f) than immune
non-responders, but statistical significance was
not reached because of the low patient number.
Specifically, the three patients ≤ 65 years who
showed an LAA-specific immune response (#6, #9
and #10) are all in ongoing CR.
Combination of 5-azacytidine with DC
vaccination as individual treatment attempt
Towards the end of the study treatment, patient
#1 developed an increase in MRD load, for both
WT1 copy number and frequency of leukaemia-
associated immunophenotype (LAIP), predicting
an impending relapse (Supplementary figure 4a).
After positive discussion with the ethics
committee of the LMU Munich and written
informed consent by the patient, we started an
individual treatment attempt combining 5-
azacytidine in the approved dose and schedule
(75 mg m2 s.c. on days 1–7 of a 28-day cycle)
with next-generation DC vaccination on day 8 and
day 15 (Supplementary figure 4a). Vaccine site
reactions were found to be considerably
enhanced (Supplementary figure 4b), and the
frequency of LAA-specific T cells was increased
(Supplementary figure 4c). Two cycles of this
combination therapy lead to MRD conversion
(Supplementary figure 4a), which lasted for some
time before the patient relapsed almost a year
later. Similar treatment attempts were later
repeated for patients #4, #7 and #11, however not
in MRD situation, but in overt relapse. Similar
results in terms of local reaction and reduction of
disease burden were not observed in these cases.
DISCUSSION
As detailed above, two clinical trials using
monocyte-derived DCs loaded with LAA-specific
mRNA have already been published.9,10 In both
studies, DCs were activated by the classical
combination of pro-inflammatory cytokines and
prostaglandins,11 and mRNA encoding a single LAA
(hTERT and WT1, respectively) was used for
electroporation. Our trial decisively differed in two
important respects. First, the TLR7/8 ligand R848
was included into the maturation protocol,
resulting in DCs with improved immunostimulatory
properties including secretion of IL-12p70, as
demonstrated in detail previously.12 This study
represents the first-in-human trial applying these
Figure 4. Swimmer plot. Time point of first CR, vaccinations, potential other treatment modalities, and relapses, death or ongoing remission are
depicted for all patients treated within the trial.
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next-generation DCs to patients. Second, three
antigens were chosen for loading of separate DC
batches.16 Next to WT1, which is very frequently
overexpressed in AML and the most prominent
antigen in vaccination trials for AML, both for DC
vaccination10,17,18 and for peptide vaccination,5 we
decided to add a second LAA in order to broaden
anti-leukaemic responses and to decrease the
possibility of immune escape. We chose PRAME as
the most prominent cancer–testis antigen in
AML.19,20 CMVpp65 as a very abundant and
immunogenic viral antigen was added for loading
of a third batch of DCs, allowing us to differentiate
between the induction of primary and secondary
immune responses by comparison of CMV-
seronegative and CMV-seropositive patients.
The primary objective of this trial using next-
generation DCs for post-remission therapy of AML
patients was to explore the feasibility of DC
generation as well as the safety of the
Figure 5. Survival analysis. OS (a, c, e) and RFS (b, d, f) of the vaccinated patients were depicted by Kaplan–Meier plots and compared by the
log-rank test. (a, b) Patients treated within the trial were compared to a closely matched cohort of 88 patients from the AML-CG registry. (c, d)
Within the study cohort, patients ≤ 65 years and > 65 years at time of diagnosis were compared. (e, f) Immune responders as defined by an
increase in LAA-specific T cells after vaccination were compared to immune non-responders.
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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vaccinations. Patients in first CR after intensive
chemotherapy, but with a high risk of relapse,
could be included. Three of the 13 patients who
were enrolled did not proceed to vaccination
because of disease-related factors (very early
relapse prior to the first vaccination; n = 2) or
because of factors related to vaccine production
(high IL-10 secretion by DCs; n = 1). The high
production of IL-10 by the DC vaccine produced
for patient #8 was unique and had never been
seen before in preclinical experiments. This
accentuates both the very high relapse risk of the
enrolled patients and the high success rate
(> 90%) in production of DCs secreting high
amounts of IL-12p70 and low amounts of IL-10.
For the other 10 patients, the generated DCs
sufficed for vaccination of all three antigens at
the minimum of six specified time points.
Median time between leukapheresis and start of
the vaccination was 25 days (Supplementary
table 1). Eight of these 10 patients completed
the full study protocol, while two were taken
off study because of early relapse, again
highlighting the unfavorable prognosis of the
included patients. We conclude that generation
and administration of next-generation DCs are
feasible in AML patients after intensive
chemotherapy, albeit early relapse can prevent
successful administration in very high-risk
patients. Judging from the 105 vaccinations that
were administered in total, tolerability of the
protocol was excellent. Only transient adverse
events were observed, and except for one grade
3 pyrexia, all adverse events were graded 1–2
(Supplementary table 2). Despite using DCs with
stronger immunostimulatory capacity compared
to prior vaccination studies, our data showed an
excellent safety profile.
As a secondary objective of the trial, we studied
immunological responses to the DC vaccinations.
Antigen loading was done by electroporation of
mRNA in order to allow for HLA-independent,
multiple-epitope antigen presentation. T-cell
responses before and after the vaccinations were
detected by multimer staining and by ELISpot. The
analysis of CMVpp65-specific T-cell responses
allowed us to distinguish between T- and B-cell
responses in latent CMV carriers in comparison with
CMV negative patients. Within our cohort, 3/10
patients were seropositive for antibodies against
human CMV. Before the vaccinations, we detected
antigen-specific T cells by tetramer and ELISpot in
all three seropositive patients (Table 2).
Interestingly, we observed an induction of a T-cell
response to CMVpp65 in all but one patient after
vaccination, and an expansion of CMVpp65-specific
T cells in seropositive patients. For one patient (#1),
we observed divergent results between ELISpot and
multimer assays, with strong upregulation of the
ELISpot response and downregulation of the
multimer-positive population. We hypothesise that
this might be interpreted as a selective expansion of
antigen-specific T cells not detected by the available
multimers or possible determinant spreading to T
cells recognising an alternative epitope. Using major
histocompatibility complex (MHC) class II multimers,
we found an increase in antigen-specific CD4+ T
cells in four of seven applicable patients (Table 2).
In two of these patients (#7, #10), this correlated
with development of antibodies against CMVpp65.
A physiological seroconversion as a result of primary
CMV infection was ruled out by missing detection
of the CMV-associated protein p150. From the data
on CMVpp65 immunomonitoring, we conclude that
next-generation DCs are capable of inducing
primary and secondary immune responses.
These are not restricted to CD8+ T-cell responses,
but also comprise CD4+ T-cell and antibody
responses.
Similarly, we were able to show the induction of
LAA-specific T-cell responses. However, in contrast
to the immune responses against CMVpp65, the
responses directed against WT1 and PRAME were
lower in frequency and not detected in all patients.
This might partially be attributed to restricted
availability of HLA-specific multimers and a random
mix of peptides with different lengths for the
ELISpot assays. Therefore, it is likely that not all
LAA-specific T cells were detected in spite of the
two complementary methods. However, differences
between a viral antigen and autoantigens certainly
play a role, with high-affinity T cells against the
latter being negatively selected in the thymus
during T-cell development. Our immunomonitoring
data provide evidence that the immunostimulatory
capacity of next-generation TLR7/8-matured DCs is
very high. Further work is needed to identify the
optimal setting for DC application, for example
induction of neoantigen-specific T cells or boosting
of genetically engineered T cells for adoptive
transfer.
In spite of the single-arm phase I design and
the limited patient number in this first-in-human
trial, we believe it is highly relevant to report
the safety and tolerability of a TLR7/8-matured
DC vaccine. The successful application of more
2020 | Vol. 9 | e1117
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than 100 vaccines demonstrates the suitability of
the vaccine, which is also applicable in other
cancer entities. Besides, we demonstrated the
induction of immunological responses.
Promising clinical outcome is suggested by the
comparison to a closely matched patient cohort.
A beneficial effect of vaccination was observed
with respect to RFS with a median survival of
1084 compared to 396 days. This effect was
more pronounced for patients of younger age
and with vaccine-induced immune responses.
Patients ≤ 65 years showed significantly better
OS and RFS than patients > 65 years. Two of the
patients in the older cohort relapsed quickly
without detection of a LAA-specific immune
response, and the third patient relapsed shortly
after termination of the vaccination protocol. In
the younger cohort, however, only two of seven
patients relapsed, and six of seven were still
alive at data cut-off. This is in line with a recent
publication, in which an overall survival benefit
was dominantly observed in the patient cohort
below 65 years of age.10 This might be related
to the larger pool of naive T cells in younger
AML patients, which are required for the
induction of novel anti-leukaemic immune
responses.21 Moreover, immune responses
against WT1 and PRAME correlated to
prolonged OS and RFS (Figure 5e and f).
Specifically, all three patients of the younger
age group that showed a leukaemia-specific
immune response remained in ongoing CR until
data cut-off. Our data support the hypothesis
that TLR7/8-matured DCs induce protective LAA-
specific immune response in patients ≤ 65 years.
However, frequency and strength of LAA-
specific immune responses need to be enhanced
in order to improve clinical benefit.
Of note, because of the very small patient
number, the comparison of survival data with the
matched patient cohort is purely exploratory and
hypothesis-generating. There was therefore no
formal statistical analysis plan for this comparison,
and multiple testing was not compensated for.
Several factors might have contributed to the
fact that the immunological and clinical effects in
this study were lower than might have been
expected. The use of autoantigens for vaccination
has been discussed above. Second, a comparison
of the DC characterisation within this trial with
the results of our preclinical experiments12,13,15
showed considerably lower CD86/PD-L1 ratio and
IL-12p70 secretion. This might be due to the
upscaling of the DC generation process including
elutriation of a leukapheresis product after
overnight storage instead of plastic adherence of
freshly isolated PBMCs.
However, we believe that combinatorial
approaches are the most promising strategy to
further enhance immune responses and hence
clinical benefit. Epigenetic modifiers such as DNA
methyltransferase inhibitors and histone
deacetylase inhibitors are suitable combination
partners because of an enhancement in antigen
processing and presentation of malignant cells.22–25
In the setting of myelodysplastic syndrome, the
combination of vaccination against NY-ESO-1 and
decitabine resulted in an increased antigen-specific
immune response.26 In our hands, the combination
of next-generation DC vaccination with 5-
azacytidine resulted in a striking increase in local
and systemic immune responses. This translated
into a temporary MRD conversion in a single
patient. We suggest pursuing this approach in
further clinical trials. Immune checkpoint blockade
is another strategy for combinational approaches.
Early clinical trials are already combining vaccines
with programmed cell death protein 1 (PD-1)
blockers for treatment of various malignancies
including AML.27 The combination of both
epigenetic modification by azacytidine and PD-1
blockade by nivolumab was recently shown to be a
safe and effective therapy for relapsed AML.28
However, other checkpoint molecules might be
even more relevant as suggested by our preclinical
data showing that blockade of lymphocyte
activation gene 3 (LAG-3) strongly enhances DC-
induced immune responses against viral and
leukaemia-associated antigens.29
CONCLUSIONS
Vaccination of high-risk AML patients with TLR7/
8-matured RNA-loaded DCs was feasible, safe and
resulted in induction of leukaemia-specific
immune responses. Explorative comparison to a
matched cohort suggests a benefit on the clinical
outcome; positive effects of vaccination on
survival were particularly seen for immune
responders and patients ≤ 65 years. Perspectively,
immune responses can be further augmented by
combining TLR7/8-matured DCs with
immunomodulatory drugs like hypomethylating
agents or checkpoint inhibitors.
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METHODS
Study design
We here report results of a phase I trial, with clinical efficacy
analysis being purely explorative. AML (excluding acute
promyelocytic leukaemia) patients at the age of 18–75 with
a non-favorable risk profile (intermediate I, intermediate II
or adverse according to European LeukemiaNet (ELN)
classification of 2010;30 or with a favorable risk according to
ELN and MRD positivity) in CR/CRi after at least one cycle of
intensive induction therapy including an anthracycline and
cytarabine were eligible for enrolment. Patients with prior
allo-HSCT, severe organ dysfunction or active clinically
relevant autoimmune disease were excluded. None of the
patients were eligible for an allo-HSCT, either because of
comorbidities, lack of donor or missing consent. The primary
objective of the study was to determine safety and
feasibility of immunotherapy with autologous DCs, resulting
in the endpoints of frequency of adverse events and
percentage of patients in whom treatment with the
scheduled number of immunotherapies (10 DC vaccinations)
was feasible. As a secondary objective, we explored the
induction of immunological responses to the DC vaccination.
Clinical responses were estimated by comparing RFS and OS
between immune responders and non-responders as well as
between all vaccinated study patients and matched control
patients of the AML-CG registry. The vaccine was
administered intradermally up to 10 times within 26 weeks
at 5 9 106 DCs for each antigen (three batches at three
separate sites) and time point, starting at weekly intervals
and continuing at four-week intervals (see Supplementary
figure 5). No other anti-leukaemia therapy was permitted in
parallel as long as the patient was in remission, but 5-
azacytidine was added to the ongoing vaccination strategy
in some patients when the criteria for a leukaemia relapse
were met. The study was mono-centric, open-label,
prospective and non-randomised. All patients with successful
vaccine generation who still met the eligibility criteria after
this process were vaccinated at the Department of Medicine
III, University Hospital, LMU Munich.
Vaccine generation
Peripheral blood mononuclear cells were collected by
leukapheresis and transported to the GMP facility of the
Department of Cellular Therapy at The Norwegian Radium
Hospital in Oslo. Monocytes were enriched from
leukapheresis using elutriation (ELUTRA, Caridian) and
cultured in RPMI 1640 medium with very low endotoxin
(Biochrom, Berlin, Germany) plus 1.5% human AB serum
(Institute of Transfusion Medicine, Suhl, Germany),
supplemented with 560 IU mL1 GM-CSF (Leukine, Bayer,
Leverkusen, Germany) and 20 ng mL1 interleukin-4 (R&D
Systems, Wiesbaden, Germany) for 40–72 h. Thereafter,
10 ng mL1 TNF-a, 10 ng mL1 IL1-b (both R&D Systems,
Wiesbaden, Germany), 5000 IU mL1 interferon-c (Imukin,
Boehringer Ingelheim, Ingelheim, Germany), 250 ng mL1
PGE2 (Prostine E2; Pfizer, Kent, UK) and 1 lg mL1 R848
(3M Pharmaceuticals, St. Paul, MN, USA) were added to the
culture medium for another 20–26 h.16 Mature DCs were
thoroughly washed and electroporated in three different
batches, each transduced with in vitro transcribed (ivt)
codon-optimised RNA (produced at Oslo University Hospital
in clinical grade) encoding for either human WT1 (isoform
A, NP_000369.3), PRAME (NP_006106.1) or CMVpp65
(P06725.2). After 2–6 h, DCs were harvested and
cryopreserved. Before the first batch of DCs was
administered to the individual patient, release criteria
including total cell number, viability, and CD80 positivity, as
well as lack of excessive contaminating cells, microbiological
contamination and mycoplasma, were controlled (see
Supplementary table 5 for details). Before administration,
cells were resuspended with 200 µL DPBS each.
Vaccine characterisation
Expression of DC surface antigens was measured by flow
cytometry using a panel of fluorescence-conjugated
monoclonal antibodies (Supplementary table 6). Dead cells
were excluded by Live/Dead Aqua (Invitrogen, Carlsbad, CA,
USA) staining and only singlets gated. Corresponding
mouse IgG isotype controls were used. After washing, cells
were analysed using a FACS LSR II (BD Biosciences). Post-
acquisition analysis was performed using FlowJo software
(version 9.7.6; Tree Star, Ashland, OR, USA). The percentage
of positive cells was determined by setting the gate at or
below 1% in the respective isotype control. SFI was
calculated as the ratio of the median fluorescence intensity
of the test sample to its corresponding isotype control.
Migration and cytokine secretion capacity of DCs were
analysed as described previously.14 To assess protein
expression of transfected RNA in DCs, the freshly thawed
cells were fixed using Foxp3 Staining Buffer Set
(eBioscience). After FcR blocking, intracellular antigen
staining was performed with anti-HCMV, anti-WT1 or anti-
PRAME, and AF647-conjugated anti-mouse F(ab)2 as
secondary antibody (Supplementary table 6). DC antigen
presentation capacity was tested in an human leucocyte
antigen (HLA)-matched 24h coculture of CMVpp65, WT1 or
PRAME RNA-transfected DCs with CMV-specific T cells
(kindly provided by A. Moosmann), WT1-specific T cells
(generated in our laboratory as previously described31) or
PRAME-specific T cells (generated as previously described32),
respectively, at a 1:10 ratio. IFN-c secretion into the
supernatant was analysed by cytometric bead array (CBA)
Human IFN-c Flex Set (BD Biosciences).
Measurement of immune responses
Local reactions at the vaccine sites were assessed by
measuring the diameter of the erythema 48h after the
fifth vaccination. Skin biopsies were taken and analysed
by immunohistochemistry for CD4+ and CD8+ T-cell
infiltration. Patients’ lymphocyte subpopulations in
peripheral blood were analysed according to standard
procedures. Human IFN-c single-colour ELISpot assays
(CTL, Bonn, Germany) were performed following the
manufacturer’s recommendations with 2µg mL1
CMVpp65, WT1 or PRAME peptide pools (JPT, Berlin,
Germany) in triplicates. Resulting spots were counted
using the ImmunoSpot S6 Analyzer’s (CTL) Smart Count
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Mode. Multimer staining was performed depending on
the patient’s HLA (Supplementary table 4) and availability
of corresponding multimers. PE-labelled multimers
(Supplementary table 6) were used for identification of
vaccine-induced CD4+ and CD8+ T cells specific for
CMVpp65, WT1 and PRAME. Multimers for HIV-Gag and
CLIP were used as controls. For detection of CMV-specific
CD4+ T cells by MHC class II multimers, PBMCs were
expanded for 7 days in the presence of 2.5 µM CMVpp65
peptide EPDVYYTSAFVFPTK (JPT) with 5 ng mL1 IL-7 und
IL-15 (PeproTech) added during the last three days. T-cell
surfaces were additionally stained for CD3, CD4 and CD8.
Patient sera were analysed for antibodies against the
single antigens of human CMV before and after
vaccination using the recomLine CMV IgG, IgM
Immunoassay (MIKROGEN, Neuried, Germany) and the
Enzygnost (Siemens Healthcare GmbH, Erlangen,
Germany). Primary CMV infection during the trial was
excluded by assessment of the study-specific p65 protein
without concomitant detection of the p150 protein.
Clinical assessments
Patients were monitored for adverse events starting from
the first screening visit until 4 weeks after the last
vaccination. All toxicities were graded according to the
National Cancer Institute Common Toxicity Criteria version
5.0. Leukaemia was assessed by routine bone marrow
diagnostics including determination of MRD by available
molecular markers and by LAIP. RFS and OS were followed
until the cut-off date of 31 March 2018 and depicted by
swimmer plot for individual patients and by Kaplan–Meier
plots.
Statistical analysis
For the analysis of ELISpot responses, the frequency of
antigen-specific T cells was calculated by subtracting the
mean number of spots in the control wells from the mean
number of spots observed in response to antigen. Prior to
the vaccination, ≥ 5 antigen-specific T cells were considered
a positive response (+ in Table 2) and ≥ 100 antigen-specific
T cells were considered a highly positive response (++).
Upregulation of an immune response to the vaccinations (↑)
was defined to be a ≥ 1.5-fold increase of antigen-specific
spot count and ≥ 5 antigen-specific T cells after
vaccinations. For determination of antigen-specific T cells by
multimer staining, the percentage of CD8+ or CD4+ T cells
stained positive with a control multimer was subtracted
from the percentage of cells stained positive with the
specific multimer. Prior to the vaccination, ≥ 0.1% antigen-
specific T cells were considered a positive response (+ in
Table 2) and ≥ 1% antigen-specific T cells were considered a
highly positive response (++). Upregulation of an immune
response to the vaccinations (↑) was defined to be a ≥ 2-
fold increase of multimer-positive CD8+ or CD4+ T cells and
≥ 0.1% antigen-specific T cells after vaccinations.
Downregulation of an immune response to the vaccinations
(↓) was defined to be a ≥ 2-fold decrease of multimer-
positive CD8+ or CD4+ T cells. An immune response to a
specific antigen was defined by upregulation of the ELISpot
and/or multimer response to the respective antigen
(Table 2). In order to compare survival data of this single-
arm trial to that of AML patients with very similar
characteristics, a carefully matched cohort of 88 patients
from the AML-CG registry was selected according to the
following criteria: CR/CRi/CRp after intensive induction
therapy; no allo-HSCT in CR1; duration of remission at least
as long as in the trial population; non-favorable risk type;
ECOG 0 or 1; and age at diagnosis 18–75. A comparison of
patient characteristics between the DC study cohort and the
AML-CG registry cohort is depicted in Supplementary table
3. Differences in survival between different groups were
tested by log-rank test.
ACKNOWLEDGMENTS
We thank Elke Habben, Sabine Reinkunz and Ewelina
Zientara for participation in flow cytometry analysis and
Marina Leeping for excellent technical assistance. This work
was supported by funds of BayImmuNet, the Bavarian
Immunotherapy Network; Helmholtz Alliance; DFG
CRC1243; and the Bavarian Elite Graduate Training Network
‘i-Target’.
CONFLICT OF INTEREST
DJS is employed by Medigene Immunotherapies GmbH, and
holds patents and receives royalties for DC vaccines. All
other authors declare that they have no conflict of interest.
AUTHORS’ CONTRIBUTIONS
FSL, WH, DJS, GK, IB and MS designed the clinical trial. FSL,
TA, VLB, TK, GW, BW, GK, IB and MS performed the clinical
trial. FMS, FSL, MR, KD, CA, NPK, KS, AM, SB, MBo, MBr,
MHMH and MS acquired and analysed the data. FSL, FMS,
MR, KD and DG performed the statistical analysis. FSL, FMS,
MR, KD, and MS designed the figures. FSL, FMS, MR and
MS wrote the manuscript.
ETHICS APPROVAL AND CONSENT TO
PARTICIPATE
The study was approved by the ethics committee of the
LMU Munich and by the Paul-Ehrlich-Institute in Langen,
Germany.
CONSENT FOR PUBLICATION
All patients provided written informed consent.
AVAILABILITY OF DATA AND
MATERIAL
The data sets used and/or analysed during the current study
are available from the corresponding author on reasonable
request.
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology Inc.
2020 | Vol. 9 | e1117
Page 15
FS Lichtenegger et al. TLR-matured dendritic cells for therapy of AML
REFERENCES
1. Noone AM, Howlader N, Krapcho Met al. SEER Cancer
Statistics Review, 1975–2015. National Cancer Institute.
Bethesda, MD. https://seer.cancer.gov/csr/1975_2015/,
based on November 2017 SEER data submission, posted
to the SEER web site, April 2018. Accessed September
27, 2018.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA
Cancer J Clin 2018; 68: 7–30.
3. Kassim AA, Savani BN. Hematopoietic stem cell
transplantation for acute myeloid leukemia: a review.
Hematol Oncol Stem Cell Ther 2017; 10: 245–251.
4. Lichtenegger FS, Schnorfeil FM, Hiddemann W,
Subklewe M. Current strategies in immunotherapy for
acute myeloid leukemia. Immunotherapy 2013; 5: 63–78.
5. Di Stasi A, Jimenez AM, Minagawa K, Al-Obaidi M,
Rezvani K. Review of the results of WT1 peptide
vaccination strategies for myelodysplastic syndromes
and acute myeloid leukemia from nine different
studies. Front Immunol 2015; 6: 36.
6. Weinstock M, Rosenblatt J, Avigan D. Dendritic cell
therapies for hematologic malignancies. Mol Ther
Methods Clin Dev 2017; 5: 66–75.
7. Lichtenegger FS, Krupka C, Haubner S, K€ohnke T,
Subklewe M. Recent developments in immunotherapy of
acute myeloid leukemia. J Hematol Oncol 2017; 10: 142.
8. Rosenblatt J, Stone RM, Uhl L et al. Individualized
vaccination of AML patients in remission is associated
with induction of antileukemia immunity and
prolonged remissions. Sci Transl Med 2016; 8: 368ra171.
9. Khoury HJ, Collins RH, Blum W et al. Immune responses
and long-term disease recurrence status after telomerase-
based dendritic cell immunotherapy in patients with
acute myeloid leukemia. Cancer 2017; 123: 3061–3072.
10. Anguille S, Van de Velde AL, Smits EL et al. Dendritic
cell vaccination as post-remission treatment to prevent
or delay relapse in acute myeloid leukemia. Blood 2017;
130: 1713–1721.
11. Jonuleit H, Kuhn U, Muller G et al. Pro-inflammatory
cytokines and prostaglandins induce maturation of
potent immunostimulatory dendritic cells under fetal
calf serum-free conditions. Eur J Immunol 1997; 27:
3135–3142.
12. Lichtenegger FS, Mueller K, Otte B et al. CD86 and IL-
12p70 are key players for T helper 1 polarization and
natural killer cell activation by Toll-like receptor-
induced dendritic cells. PLoS One2012; 7: e44266.
13. Spranger S, Frankenberger B, Schendel DJ. NOD/scid IL-
2Rgnull mice: a preclinical model system to evaluate
human dendritic cell-based vaccine strategies in vivo. J
Transl Med 2012; 10: 30.
14. Beck B, D€orfel D, Lichtenegger FS et al. Effects of TLR
agonists on maturation and function of 3-day dendritic
cells from AML patients in complete remission. J Transl
Med 2011; 9: 151.
15. Spranger S, Javorovic M, B€urdek M et al. Generation of
Th1-polarizing dendritic cells using the TLR7/8 agonist
CL075. J Immunol 2010; 185: 738–747.
16. Subklewe M, Geiger C, Lichtenegger FS et al. New
generation dendritic cell vaccine for immunotherapy of
acute myeloid leukemia. Cancer Immunol Immunother
2014; 63: 1093–1103.
17. Van Tendeloo VF, Van de Velde A, Van Driessche A
et al. Induction of complete and molecular remissions
in acute myeloid leukemia by Wilms’ tumor 1 antigen-
targeted dendritic cell vaccination. Proc Natl Acad Sci
USA 2010; 107: 13824–13829.
18. Shah NN, Loeb DM, Khuu H et al. Induction of immune
response after allogeneic Wilms’ tumor 1 dendritic cell
vaccination and donor lymphocyte infusion in patients
with hematologic malignancies and post-
transplantation relapse. Biol Blood Marrow Transplant
2016; 22: 2149–2154.
19. Atanackovic D, Luetkens T, Kloth B et al. Cancer-testis
antigen expression and its epigenetic modulation in
acute myeloid leukemia. Am J Hematol 2011; 86: 918–
922.
20. Ding K, Wang XM, Fu R, Ruan EB, Liu H, Shao ZH.
PRAME gene expression in acute leukemia and its
clinical significance. Cancer Biol Med 2012; 9: 73–76.
21. Schnorfeil FM, Lichtenegger FS, Emmerig K et al. T cells
are functionally not impaired in AML: Increased PD-1
expression is only seen at time of relapse and correlates
with a shift towards the memory T cell compartment. J
Hematol Oncol 2015; 8: 93.
22. Yao Y, Zhou J, Wang L et al. Increased PRAME-specific
CTL killing of acute myeloid leukemia cells by either a
novel histone deacetylase inhibitor chidamide alone or
combined treatment with decitabine. PLoS One 2013; 8:
e70522.
23. Srivastava P, Paluch BE, Matsuzaki J et al. Induction of
cancer testis antigen expression in circulating acute
myeloid leukemia blasts following hypomethylating
agent monotherapy. Oncotarget 2016; 7: 12840–12856.
24. Siebenk€as C, Chiappinelli KB, Guzzetta AA et al.
Inhibiting DNA methylation activates cancer testis
antigens and expression of the antigen processing and
presentation machinery in colon and ovarian cancer
cells. PLoS One2017; 12: e0179501.
25. Luo N, Nixon MJ, Gonzalez-Ericsson PI et al. DNA
methyltransferase inhibition upregulates MHC-I to
potentiate cytotoxic T lymphocyte responses in breast
cancer. Nat Commun 2018; 9: 248.
26. Griffiths EA, Srivastava P, Matsuzaki J et al. NY-ESO-1
vaccination in combination with decitabine induces
antigen-specific T-lymphocyte responses in patients
with myelodysplastic syndrome. Clin Cancer Res 2018;
24: 1019–1029.
27. Versteven M, Van den Bergh JMJ, Marcq E et al.
Dendritic cells and programmed death-1 blockade: a
joint venture to combat cancer. Front Immunol 2018; 9:
394.
28. Daver N, Garcia-Manero G, Basu S et al. Efficacy, safety,
and biomarkers of response to azacitidine and
nivolumab in relapsed/refractory acute myeloid
leukemia: a nonrandomized, open-label, phase II study.
Cancer Discov 2019; 9: 370–383.
29. Lichtenegger FS, Rothe M, Schnorfeil FM et al. Targeting
LAG-3 and PD-1 to enhance T cell activation by antigen-
presenting cells. Front Immunol 2018; 9: 385.
30. D€ohner H, Estey EH, Amadori S et al. Diagnosis and
management of acute myeloid leukemia in adults:
recommendations from an international expert panel,
on behalf of the European LeukemiaNet. Blood 2010;
115: 453–474.
2020 | Vol. 9 | e1117
Page 16
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology Inc.
TLR-matured dendritic cells for therapy of AML FS Lichtenegger et al.
31. W€olfl M, Greenberg PD. Antigen-specific activation and
cytokine-facilitated expansion of naive, human CD8+ T
cells. Nat Protoc 2014; 9: 950–966.
32. Amir AL, van der Steen DM, van Loenen MM et al.
PRAME-specific Allo-HLA-restricted T cells with potent
antitumor reactivity useful for therapeutic T-cell
receptor gene transfer. Clin Cancer Res 2011; 17: 5615–
25.
Supporting Information
Additional supporting information may be found
online in the Supporting Information section at
the end of the article.
This is an open access article under the terms of
the Creative Commons Attribution License,
which permits use, distribution and reproduction
in any medium, provided the original work is
properly cited.
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology Inc.
2020 | Vol. 9 | e1117
Page 17
FS Lichtenegger et al. TLR-matured dendritic cells for therapy of AML
